Harbor Capital Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Harbor Capital Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.74M	Buy	+83,196	New	+$1.87M	0.14%	220
2024 Q1	–	Sell	-34,930	Closed	-$1.67M	–	837
2023 Q4	$1.67M	Buy	34,930 +3,048	+10%	+$118K	0.32%	81
2023 Q3	$1.14M	Buy	31,882 +5,910	+23%	+$234K	0.24%	103
2023 Q2	$1.2M	Buy	+25,972	New	+$1.2M	0.24%	105
2023 Q1	–	Sell	-2,264	Closed	-$105K	–	269
2022 Q4	$105K	Buy	2,264 +469	+26%	+$18.4K	0.1%	85
2022 Q3	$74K	Sell	1,795 -1,123	-38%	-$57.7K	0.07%	134
2022 Q2	$174K	Buy	2,918 +592	+25%	+$36.4K	0.13%	87
2022 Q1	$169K	Buy	+2,326	New	+$162K	0.08%	113

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Harbor Capital Advisors's RARE Position: Q1 2026 in Review

Harbor Capital Advisors opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 83,196 shares worth $1.74M. The stake represents 0.14% of the portfolio and ranks #220 among its holdings. This is a return to the name: Harbor Capital Advisors previously reported a position in RARE as recently as Q4 2023.

Harbor Capital Advisors first reported a position in RARE in Q1 2022 and has held it in 8 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Harbor Capital Advisors held 83,196 shares of Ultragenyx Pharmaceutical worth $1.74M as of Q1 2026.
Ultragenyx Pharmaceutical was a new Harbor Capital Advisors position in Q1 2026.
Ultragenyx Pharmaceutical made up 0.14% of Harbor Capital Advisors's portfolio in Q1 2026, its #220 holding.
Harbor Capital Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2022 and has held it in 8 quarters since.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.